证券代码：002793 股票简称：罗欣药业 公告编号：2025-064 罗欣药业集团股份有限公司 关于更换重大资产重组独立财务顾问主办人的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 中泰证券股份有限公司（以下简称"中泰证券"）作为罗欣药业集团股份有 限公司（以下简称"公司""罗欣药业"）重大资产置换及发行股份购买资产项 目（以下简称"重大资产重组"）的独立财务顾问，中泰证券指派高旭佳、李帅 担任独立财务顾问主办人。截至本公告披露日，重大资产重组已实施完毕，法定 持续督导期至 2022 年 12 月 31 日。公司重大资产重组的业绩承诺补偿股份回购 注销事宜已于 2022 年内完成，鉴于未退还分红款的交易对方，其持有的所有限 售股份暂不解禁上市流通，中泰证券需要对相关事宜继续履行持续督导义务。 本次调整后，中泰证券关于罗欣药业重大资产重组项目于持续督导期间的独 立财务顾问主办人为高旭佳先生和张世邦先生。本次更换独立财务顾问主办人的 事项不会对公司的生产经营造成风险和影响。 特此公告。 罗欣药业集团股份有限公司董事会 2025 年 7 月 29 日 1 ...

Core Viewpoint - The chemical pharmaceutical sector experienced a significant increase of 2.47% on July 29, with Nanjing Pharmaceutical leading the gains [1] Group 1: Market Performance - The Shanghai Composite Index closed at 3609.71, up 0.33% [1] - The Shenzhen Component Index closed at 11289.41, up 0.64% [1] Group 2: Individual Stock Performance - Nanjing Pharmaceutical (681899) closed at 11.90, with a rise of 17.01% and a trading volume of 388,700 shares, totaling a transaction value of 417 million yuan [1] - Yuandong Biological (688513) closed at 65.92, up 15.45%, with a trading volume of 74,200 shares and a transaction value of 466 million yuan [1] - Microchip Biotech (688321) closed at 38.37, increasing by 12.85%, with a trading volume of 401,800 shares and a transaction value of 1.49 billion yuan [1] - Aoxiang Pharmaceutical (603229) closed at 10.54, up 10.02%, with a trading volume of 480,600 shares and a transaction value of 493 million yuan [1] - Asia-Pacific Pharmaceutical (002370) closed at 6.81, also up 10.02%, with a trading volume of 1,937,200 shares and a transaction value of 1.285 billion yuan [1] - Chenxin Pharmaceutical (603367) closed at 25.93, up 10.01%, with a trading volume of 160,000 shares and a transaction value of 413 million yuan [1] - Fuyuan Pharmaceutical (6801089) closed at 22.90, increasing by 9.99%, with a trading volume of 176,900 shares and a transaction value of 389 million yuan [1] - Nikan Pharmaceutical (688658) closed at 33.02, up 9.96%, with a trading volume of 118,700 shares and a transaction value of 376 million yuan [1] - Luoxin Pharmaceutical (002793) closed at 5.97, increasing by 9.94%, with a trading volume of 421,300 shares and a transaction value of 240 million yuan [1] - Frontier Biotech (688221) closed at 22.42, up 9.74%, with a trading volume of 471,400 shares and a transaction value of 1.023 billion yuan [1] Group 3: Capital Flow - The chemical pharmaceutical sector saw a net inflow of 1.295 billion yuan from main funds, while retail funds experienced a net outflow of 1.198 billion yuan [1] - Speculative funds recorded a net outflow of 97.108 million yuan [1]

证券代码：002793 证券简称：罗欣药业 公告编号：2025-062 罗欣药业集团股份有限公司 关于为控股子公司提供担保的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 罗欣药业集团股份有限公司（以下简称"公司"）及控股子公司对外担保总 额超过最近一期经审计净资产 100%；公司及控股子公司担保金额超过上市公司 最近一期经审计净资产 50%，提请投资者充分关注担保风险。 一、担保情况概述 为满足日常生产经营及业务拓展资金需要，保证生产经营持续发展和业务顺 利开展，公司拟为其控股子公司山东罗欣药业集团股份有限公司（以下简称"山 东罗欣"）人民币 86,000 万元银行授信额度提供担保。公司分别于 2025 年 1 月 20 日、2025 年 2 月 7 日召开第五届董事会第二十二次会议、第五届监事会第十 九次会议及 2025 年第一次临时股东大会，审议通过了《关于为控股子公司提供 担保的议案》。具体内容详见公司于 2025 年 1 月 21 日刊登于巨潮资讯网 （http://www.cninfo.com.cn）的《关于为控股子公司提供担 ...

Core Viewpoint - The announcement details the pledge and release of shares by the controlling shareholder of Luoxin Pharmaceutical Group Co., Ltd., indicating changes in shareholding structure and potential implications for the company's financial health and governance [1][2]. Share Pledge Situation - Luoxin Holdings, the controlling shareholder, pledged 25,000,000 shares, accounting for 10.55% of its holdings and 2.30% of the total shares of the company [1]. - The purpose of the pledge is for capital turnover, with the pledge starting on July 17 and set to expire on an unspecified date [1]. Share Release Situation - Luoxin Holdings released 16,500,000 shares from pledge, which represents 6.96% of its holdings and 1.52% of the total shares of the company [1]. - The release occurred on August 18, with the shares previously pledged starting from an unspecified date [1]. Cumulative Pledge Situation - As of the announcement date, the total pledged shares by Luoxin Holdings and its concerted parties amount to 102,443,530 shares, which is 43.23% of the shares held by the controlling shareholder and 9.42% of the total shares of the company [2]. - The corresponding financing balance for these pledged shares is 172.5 million yuan [2]. Financial Health of Shareholders - The controlling shareholder and its concerted parties are reported to have a good credit status and possess the financial capability to repay the pledged amounts [2].

Financing and Guarantee Overview - The company plans to continue financing leasing business for its subsidiaries, with a total amount not exceeding 150 million RMB, authorized for a period of 12 months from the board's approval date [1][2] - The company and its subsidiaries intend to provide guarantees totaling up to 648 million RMB for the year 2025, which includes various forms of guarantees among subsidiaries [2][3] Guarantee Progress - The company has provided irrevocable joint liability guarantees for financing leases of 20 million RMB for Shandong Luoxin and 30 million RMB for Shandong Yuxin, within the approved limits [3][8] - After the guarantees, the total guarantee balance for Shandong Luoxin will be 1,164.82 million RMB, with a remaining guarantee capacity of 797.79 million RMB [3][8] - For Shandong Yuxin, the total guarantee balance will be 30 million RMB, with a remaining guarantee capacity of 81 million RMB [3][8] Financial Data of Subsidiaries - Shandong Luoxin reported total assets of 4,972.40 million RMB and total liabilities of 2,756.94 million RMB for the year 2024, with a net profit of -632.30 million RMB [5] - Shandong Yuxin reported total assets of 909.11 million RMB and total liabilities of 635.76 million RMB for the year 2024, with a net profit of -1,160.44 million RMB [6] Board's Opinion - The board believes that engaging in financing leasing will effectively meet the company's operational funding needs and optimize the capital structure [8] - The company maintains effective control over Shandong Luoxin, ensuring manageable risk levels for the guarantees provided [8] Total Guarantee Amount - After the new guarantees, the total guarantee amount by the company and its subsidiaries will be 2,538 million RMB, representing 183.61% of the latest audited net assets [9]

证券代码：002793 证券简称：罗欣药业 公告编号：2025-061 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 罗欣药业集团股份有限公司（以下简称"公司"）及控股子公司对外担保总 额超过最近一期经审计净资产 100%；公司及控股子公司担保金额超过上市公司 最近一期经审计净资产 50%；本次进展公告涉及对资产负债率超过 70%的控股 子公司提供担保，提请投资者充分关注担保风险。 一、融资租赁及担保情况概述 （一）融资租赁情况概述 1、公司控股子公司于 2024 年 10 月开展融资租赁业务，总金额为 1 亿元。 具体内容详见公司于 2024 年 10 月 25 日 刊 登 于 巨 潮 资 讯 网 （http://www.cninfo.com.cn）的《关于为控股子公司开展融资租赁业务提供担保 的公告》。现因控股子公司生产经营需要，拟继续开展融资租赁业务，公司于 2025 年 7 月 21 日召开第五届董事会第二十六次会议，审议通过了《关于开展融资租 赁业务的议案》。公司同意控股子公司继续以部分资产售后回租等方式开展融资 租赁业务，拟开展融资租 ...

| 股东名称 | 是否为控股 股东或第一 | 本次解除质 | 占其所 | 占公司 | 质押起始 | | 解除日期 | | 质权人 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 大股东及其 | 押股份数量 | 持股份 | 总股本 | 日 | | | | | | | 一致行动人 | （股） | 比例(%) | 比例(%) | | | | | | | 罗欣控股 | 是 | 16,500,000 | 6.96 | 1.52 | 年 2025 1 月 23 | 日 | 年 2025 7 月 18 | 日 | 深圳市佳 银典当有 | | | | | | | | | | | 限公司 | | 合计 | - | 16,500,000 | 6.96 | 1.52 | - | | - | | - | 1 证券代码：002793 股票简称：罗欣药业 公告编号：2025-058 罗欣药业集团股份有限公司 关于控股股东部分股份质押及解除质押的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 罗欣 ...

证券代码：002793 股票简称：罗欣药业 公告编号：2025-060 罗欣药业集团股份有限公司 （一）审议通过《关于开展融资租赁业务的议案》 公司控股子公司于 2024 年 10 月开展融资租赁业务，总金额为 1 亿元。具体 内容详见公司于 2024 年 10 月 25 日刊登于巨潮资讯网（http://www.cninfo.com.cn） 的《关于为控股子公司开展融资租赁业务提供担保的公告》。现因控股子公司生 产经营需要，拟继续开展融资租赁业务，公司同意控股子公司以部分资产售后回 租等方式开展融资租赁业务，拟开展融资租赁业务总金额不超过 1.5 亿元人民币， 以上额度的使用期限自该事项获董事会审议通过之日起 12 个月。具体内容详见 同日刊登于巨潮资讯网、《上海证券报》（http://www.cninfo.com.cn）的《关于控股 子公司开展融资租赁业务暨担保进展的公告》。 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 罗欣药业集团股份有限公司监事会 一、监事会会议召开情况 2025 年 7 月 21 日，罗欣药业集团股份有限公司（以下简称"公司"）第 ...

证券代码：002793 股票简称：罗欣药业 公告编号：2025-059 罗欣药业集团股份有限公司 1 网（http://www.cninfo.com.cn）、《上海证券报》的《关于控股子公司开展融资租 赁业务暨担保进展的公告》。 第五届董事会第二十六次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 2025 年 7 月 21 日，罗欣药业集团股份有限公司（以下简称"公司"）第五 届董事会第二十六次会议在山东省临沂高新技术产业开发区罗七路管理中心三 楼会议室和上海市浦东新区前滩世贸中心会议室以现场表决和通讯表决相结合 的方式召开。会议通知已于 2025 年 7 月 18 日以电话、专人送达、电子邮件等方 式发出。本次会议应出席董事 5 名，实际出席董事 5 名，公司监事、董事会秘书 列席了会议。公司董事长刘振腾先生主持了本次会议。会议的召集、召开符合《中 华人民共和国公司法》（以下简称"《公司法》"）等法律法规、规范性文件和《罗 欣药业集团股份有限公司章程》（以下简称"《公司章程》"）的规定，合法有 效。 二、董事会会议审议 ...

Summary of Key Points Core Viewpoint - The company, 罗欣药业, is providing a guarantee for its subsidiary, 山东罗欣, to secure a bank credit line of 860 million RMB, which raises the total guarantee amount to 1,144.82 million RMB, indicating a significant commitment to support its subsidiary's operations and growth [1][2]. Group 1: Guarantee Overview - The company plans to provide a guarantee of 860 million RMB for its subsidiary, 山东罗欣, to meet operational and expansion funding needs [1]. - The total guarantee amount for 山东罗欣 before this new guarantee was 1,050.82 million RMB, which will increase to 1,144.82 million RMB after this transaction [2]. Group 2: Financial Status of the Subsidiary - 山东罗欣 is not a dishonored debtor and has a good credit status, with normal operational activities [2]. - The financial data for 山东罗欣 shows total assets of 4,972.40 million RMB, total liabilities of 2,756.94 million RMB, and net assets of 2,215.47 million RMB for the year 2024 [4]. Group 3: Board's Opinion - The board believes that providing this guarantee will enhance financing efficiency and reduce costs, ensuring normal operations for both the company and its subsidiary [5]. - The company maintains effective control over 山东罗欣, which is expected to manage its operations well, thus keeping the risks associated with the guarantee within a controllable range [5]. Group 4: Total Guarantee Amount - After this guarantee, the total guarantee amount by the company and its subsidiaries will be 2,538 million RMB, which is 183.61% of the latest audited net assets [6]. - The total balance of external guarantees after this transaction will be 1,178.22 million RMB, accounting for 85.24% of the latest audited net assets [6].